- intellectual property | technology transfer
- Monday 12 June 2023, 10:30 - 12:00 (CEST)
- Online only
- Live streaming available
European IP Helpdesk, in cooperation with the EPO’s Patent Academy
Adéla Dvořáková, European Research Executive Agency
Level of Expertise:
According to estimates from the World Health Organization (WHO), cancer is one of the leading causes of death before the age of 70 years in over 100 countries. Worldwide, almost 20 million new cancer cases and almost 10 million cancer deaths occurred in 2020 alone. Thus, it is no surprise that the global cancer therapy market surpassed USD 150 billion in 2020 and is expected to double by the end of this decade.
Start-ups and universities play a significant role in this market since they are often the first to develop new diagnostic approaches, new drugs and therapies and work closely together to conduct research and clinical trials. The EPO has developed a new set of innovation case studies covering three cases to highlight the importance of smart IP strategy and management to facilitate the exploitation and commercialisation of novel technologies to fight cancer.
In this session, we will hear how two scientists-turned-entrepreneurs have advanced a technology platform for immunology vaccines, enabling treatments for allergies and cancer. Based on a strong patent portfolio, they founded the company and several other start-up companies for product development and technology commercialisation. IP was essential for attracting investment and generating licensing revenues early on to finance the long time-to-market periods that are typical in biotechnology.
Adéla Dvořáková, an IP expert currently working for the European Research Executive Agency and co-author of the case study, will share first-hand insights and key takeaways from their journey and will be answering individual questions from participants in a "Q&A" session.
Assistance: For any technical assistance or questions, please contact the training team at: trainingiprhelpdesk [dot] eu (training[at]iprhelpdesk[dot]eu)